Farmacie pro praxi. 2023;19(1):15-18 | DOI: 10.36290/lek.2023.002

Latest advances in psychopharmacotherapy: what a pharmacist should know

Eva Češková1, 2, 3
1 Psychiatrická klinika LF MU a FN Brno
2 KPN LF Univerzity Ostrava
3 Oddělení psychiatrie FN Ostrava

The introduction section deals with the general principles of pharmacotherapy and possible ways of treatment optimization. Furthermore, the paper summarizes the latest developments in treating schizophrenic and depressive disorders, the major examples of serious psychiatric disorders, and presents new approaches that are already available (novel second-generation antipsychotics, augmentation). In the final section, agents with a mechanism of action other than the commonly used antipsychotic drugs and antidepressants are mentioned.

Keywords: therapeutic drug monitoring, pharmacogenomic testing, schizophrenia, depressive disorder, novel second-generation antipsycho­tics, multimodal antidepressants.

Accepted: February 17, 2023; Published: March 3, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Latest advances in psychopharmacotherapy: what a pharmacist should know. Pharmacy for Practice. 2023;19(1):15-18. doi: 10.36290/lek.2023.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ceskova E. The need to improve current psychopharmacotherapy before developing new drugs. Expert Opin Pharmacother. 2014;15:1969-73. Go to original source... Go to PubMed...
    2. Frazer A, Blier P. A neuroscience­‑based nomenclature (NbN) for psychotropic agents. Int J Neuropsychopharmacol. 2016;12: yw066. Go to original source...
    3. Ustohal L. Nová nomenklatura psychofarmak. Psychiatr. praxi 2016;17:98-102. Go to original source...
    4. Češková E, Šilhán P, Kacířová I et al. Terapeutické monitorování léčiv v psychiatrii, https://postupy­‑pece.psychiatrie.cz/lecba
    5. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018;51:9-62. Go to original source... Go to PubMed...
    6. Prokeš M, Suchopár J. Lékové interakce v psychiatrii - teorie a praxe Psychiatr. praxi. 2015;16:51-55.
    7. Bousman CA, Bengesser SA, Aitchison KJ et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry 2021;54:5-17. Go to original source... Go to PubMed...
    8. Bradley P, Shiekh M, Mehra V et al. Improved efficacy with targeted pharmacogenetic­‑guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:100-107. Go to original source... Go to PubMed...
    9. Corponi F, Fabbri C, Bitter I et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971-985. Go to original source... Go to PubMed...
    10. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525-1535. Go to original source...
    11. Freudenreich O. What is the role of digital medicine for adherence monitoring in patients with serious mental illness? J Clin Psychiatry. 2022;83:22com14443. Go to original source...
    12. Dodd S, Bauer M, Carvalho AF et al. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough? World J Biol Psychiatry. 2021;22:483-494. Go to original source...
    13. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. Neuropsychiatr Dis Treat. 2018;14:741-747. Go to original source...
    14. McIntyre RS, Rosenblat JD, Nemeroff CB et al. Synthesizing the Evidence for Ketamine and esketamine in treatment­‑resistant depression: An international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383-399. Go to original source... Go to PubMed...
    15. Köhler­‑Forsberg O, N Lydholm C, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti­‑inflammatory treatment on major depressive disorder or depressive symptoms: meta­‑analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404-419. Go to original source... Go to PubMed...
    16. Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. Front Psychiatry. 2020;11:160. Go to original source...
    17. Fitton R, Sweetman J, Heseltine­‑Carp W, van der Feltz­‑Cornelis. Ch Anti­‑inflammatory medications for the treatment of mental disorders: A scoping review. Brain Behav Immun Health. 2022;26:100518. Go to original source...
    18. Mazza MG, Raffaella Zanardi R, Palladini M, Rovere­‑Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post­‑COVID depression. Eur Neuropsychopharmacol. 2022;54:1-6. Go to original source... Go to PubMed...
    19. Firth J, Solmi M, Wootton RE et al. A meta­‑review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19:360-380. Go to original source... Go to PubMed...
    20. Sarris J, Ravindran A, Yatham LN et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23:424-455. Go to original source...
    21. Nikolova VL, Hall MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in gut microbiota composition in psychiatric disorders: A Review and meta­‑analysis. JAMA Psychiatry. 2021; 78:1343-1354. Go to original source...
    22. Nikolova VL, Cleare AJ, Young AH, Stone JM. Updated review and meta­‑analysis of probiotics for the treatment of clinical depression: Adjunctive vs. stand­‑alone treatment. J Clin Med. 2021;10:647. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.